Anti-inflammatory effects of saxagliptin and vildagliptin against doxorubicin-induced nephrotoxicity in rats: attenuation of NLRP3 inflammasome up-regulation and tubulo-interstitial injury
Background and purpose: The clinical use of the chemotherapeutic drug, doxorubicin (DXR), is significantly limited by its extensive multi-organ toxicity. Dipeptidyl peptidase-4 (DPP4) is over-expressed in oxidative stress, inflammation and apoptosis. DPP4 inhibitors have proven pleiotropic effects....
Main Authors: | Rasha Ezzat Mostafa, Azza Hassan Morsi, Gihan Farag Asaad |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Research in Pharmaceutical Sciences |
Subjects: | |
Online Access: | http://www.rpsjournal.net/article.asp?issn=1735-5362;year=2021;volume=16;issue=5;spage=547;epage=558;aulast=Mostafa |
Similar Items
-
SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01) -
Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01) -
The Effect of the Chronic Administration of DPP4-Inhibitors on Systemic Oxidative Stress in Rats with Diabetes Type 2
by: Bolevich Stefani, et al.
Published: (2019-09-01) -
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
by: Pia S. Pollack, et al.
Published: (2017-09-01) -
Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01)